Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study

Affiliations

• ¹ Department of Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital, Rome, Sapienza, University of Rome, Rome, Italy.
• ² Amgen Research (Munich) GmbH, Munich, Germany. gerhardz@amgen.com.
• ³ Amgen Research (Munich) GmbH, Munich, Germany.
• ⁴ Department for Children and Adolescents, University Hospital Frankfurt, Frankfurt, Germany.
• ⁵ St Jude Children's Research Hospital, Memphis, TN, USA.
• ⁶ University Children's Hospital Wuerzburg, Wuerzburg, Germany.
• ⁷ Department of Pediatric Oncology, Children's Research Centre, University Children's Hospital Zurich, Zurich, Switzerland.
• ⁸ Department of Hematology/Oncology, University Children's Hospital Tuebingen, Tuebingen, Germany.
• ⁹ Pediatric Hematology and Immunology Department, Robert Debre Hospital, APHP, Paris, France.
• ¹⁰ Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany.
• ¹¹ Department of Pediatrics, Division of Oncology and Hematology, Charité Universitätsmedizin Berlin, Berlin, Germany.